Published in Arterioscler Thromb Vasc Biol on February 05, 2010
PEITHO Pulmonary Embolism Thrombolysis Study (PEITHO) | NCT00639743
New insights into the mechanisms of venous thrombosis. J Clin Invest (2012) 1.32
Role of tissue factor in venous thrombosis. Annu Rev Physiol (2011) 1.09
DVT: a new era in anticoagulant therapy. Arterioscler Thromb Vasc Biol (2010) 0.84
Iliofemoral deep vein thrombosis after tibial plateau fracture fixation related to undiagnosed May-Thurner syndrome: a case report. Patient Saf Surg (2013) 0.79
Medical management of venous thromboembolism: what the interventional radiologist needs to know. Semin Intervent Radiol (2012) 0.78
Aggressive management of pulmonary embolism. Semin Intervent Radiol (2012) 0.77
Post-operative Bleeding Risk in Dental Surgery for Patients on Oral Anticoagulant Therapy: A Meta-analysis of Observational Studies. Front Pharmacol (2017) 0.75
Adherence to Venous Thromboprophylaxis Guidelines for Medical and Surgical Inpatients of Teaching Hospitals, Shiraz-Iran. Tanaffos (2015) 0.75
Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 16.17
Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med (2009) 9.17
Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet (2008) 9.10
Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 7.12
A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med (2009) 4.46
Below-knee elastic compression stockings to prevent the post-thrombotic syndrome: a randomized, controlled trial. Ann Intern Med (2004) 3.74
The epidemiology of venous thromboembolism in the community. Arterioscler Thromb Vasc Biol (2008) 3.50
Incidence of venous thromboembolism: a community-based study in Western France. EPI-GETBP Study Group. Groupe d'Etude de la Thrombose de Bretagne Occidentale. Thromb Haemost (2000) 3.21
Trial of different intensities of anticoagulation in patients with prosthetic heart valves. N Engl J Med (1990) 3.19
Catheter-directed thrombolysis for lower extremity deep venous thrombosis: report of a national multicenter registry. Radiology (1999) 2.62
Prognostic value of troponins in acute pulmonary embolism: a meta-analysis. Circulation (2007) 2.54
Prognostic value of right ventricular dysfunction in patients with haemodynamically stable pulmonary embolism: a systematic review. Eur Heart J (2008) 2.51
Post-thrombotic syndrome, recurrence, and death 10 years after the first episode of venous thromboembolism treated with warfarin for 6 weeks or 6 months. J Thromb Haemost (2006) 2.32
Massive pulmonary embolism. Circulation (2006) 2.27
Randomised trial of effect of compression stockings in patients with symptomatic proximal-vein thrombosis. Lancet (1997) 2.20
The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. Haematologica (2007) 2.00
Catheter-directed thrombolysis vs. anticoagulant therapy alone in deep vein thrombosis: results of an open randomized, controlled trial reporting on short-term patency. J Thromb Haemost (2009) 1.95
Determinants of health-related quality of life during the 2 years following deep vein thrombosis. J Thromb Haemost (2008) 1.67
Risk stratification and outcomes in hemodynamically stable patients with acute pulmonary embolism: a prospective, multicentre, cohort study with three months of follow-up. J Thromb Haemost (2009) 1.55
Post-thrombotic syndrome: prevalence, prognostication and need for progress. Br J Haematol (2009) 1.27
Clinical risk factors and timing of recurrent venous thromboembolism during the initial 3 months of anticoagulant therapy. Arch Intern Med (2000) 1.24
Unsuspected pulmonary emboli in cancer patients: clinical correlates and relevance. J Clin Oncol (2006) 1.21
Call to action to prevent venous thromboembolism. J Vasc Surg (2009) 1.17
New antithrombotic drugs. Clin Pharmacol Ther (2009) 1.15
Prevalence and significance of asymptomatic venous thromboembolic disease found on oncologic staging CT. AJR Am J Roentgenol (2007) 1.14
Venous thromboembolism and bleeding in a community setting. The Worcester Venous Thromboembolism Study. Thromb Haemost (2009) 1.09
Bleeding in patients receiving vitamin K antagonists who would have been excluded from trials on which the indication for anticoagulation was based. Blood (2008) 1.01
Venous thromboembolism in the elderly. A community-based perspective. Thromb Haemost (2008) 0.99
Comparative study on risk factors and early outcome of symptomatic distal versus proximal deep vein thrombosis: results from the OPTIMEV study. Thromb Haemost (2009) 0.96
Clinical outcome of patients with major bleeding after venous thromboembolism. Findings from the RIETE Registry. Thromb Haemost (2008) 0.96
Is it worth diagnosing and treating distal deep vein thrombosis? No. J Thromb Haemost (2007) 0.92
Clinical relevance of distal deep vein thrombosis. Curr Opin Pulm Med (2008) 0.87
Suspected and incidental pulmonary embolism on multidetector-row CT: analysis of technical and morphological factors influencing the diagnosis in a cross-sectional cancer centre patient cohort. Clin Radiol (2006) 0.86
Use of pulse oximetry to predict in-hospital complications in normotensive patients with pulmonary embolism. Am J Med (2003) 0.86
Venous thromboembolism: contemporary diagnostic and therapeutic aspects. Vasa (2008) 0.85
Comparison of the clinical history of symptomatic isolated distal deep-vein thrombosis vs. proximal deep vein thrombosis in 11 086 patients. J Thromb Haemost (2009) 0.85
Deep venous thrombosis: the opportunity at hand. AJR Am J Roentgenol (2009) 0.79
Plasma protein profiling: unique and stable features of individuals. Proteomics (2005) 1.11
Anthracycline treatment of the human monocytic leukemia cell line THP-1 increases phosphatidylserine exposure and tissue factor activity. Thromb Res (2011) 0.91
O-glycoside biomarker of apolipoprotein C3: responsiveness to obesity, bariatric surgery, and therapy with metformin, to chronic or severe liver disease and to mortality in severe sepsis and graft vs host disease. J Proteome Res (2009) 0.90
A functional polymorphism of apolipoprotein C1 detected by mass spectrometry. FEBS J (2006) 0.83
Warfarin and the antiphospholipid syndrome: does one size fit all? Arthritis Rheum (2007) 0.78
Top-down proteomic analysis by MALDI-TOF profiling: Concentration-independent biomarkers. Proteomics Clin Appl (2008) 0.78